Patents by Inventor Haushabhau Shivaji Pagire

Haushabhau Shivaji Pagire has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210155634
    Abstract: The present invention relates to a novel tryptophan hydroxylase inhibitor and a pharmaceutical composition including same, wherein the novel tryptophan hydroxylase inhibitor has an excellent inhibitory effect on TPH1, and thus can be usefully used for the prevention or treatment of disorders, such as metabolic disorders, cancer, digestive or cardiovascular system disorders, related to TPH1 activity. In particular, the novel tryptophan hydroxylase inhibitor has an excellent treatment effect on inflammatory bowel disorders, and thus can be usefully used for the treatment of inflammatory bowel disorder.
    Type: Application
    Filed: August 24, 2018
    Publication date: May 27, 2021
    Inventors: Jin Hee Ahn, Hail Kim, Jaemyoung Suh, In-Kyu Lee, Kwang-eun Kim, Kun-Young Park, Eun Jung Bae, Ko Eun Shong, Suvarna Haus-habhau Pagire, Ajin Lim, Jae-Han Jeon, Haushabhau Shivaji Pagire, Haiying Zhang, Myung-Hwa Kim, Jung-In Pyo
  • Publication number: 20210070718
    Abstract: The present invention relates to a novel phenylsulfonyl oxazole derivative and a use thereof and specifically, to a compound represented by Chemical Formula 1 in the present specification or a pharmaceutically acceptable salt thereof, and to a use thereof for prevention, treatment, or improvement of neurodegenerative disease.
    Type: Application
    Filed: January 10, 2019
    Publication date: March 11, 2021
    Inventors: Jae Sung BAE, Hee Kyung JIN, Myung Shik LEE, Hye Jin LIM, Jin Hee AHN, Haushabhau Shivaji PAGIRE, Min Jae Lee
  • Publication number: 20130096347
    Abstract: Provided herein is a novel, commercially viable and industrially advantageous process for the preparation of 3-[(1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol (Tapentadol), or a pharmaceutically acceptable salt thereof, and its intermediates, in high yield and purity. Provided also herein are novel solid state forms of tapentadol intermediates and processes for their preparation thereof. Provided further herein is a purification process for preparing highly pure tapentadol hydrochloride.
    Type: Application
    Filed: April 4, 2011
    Publication date: April 18, 2013
    Applicant: ACTAVIS GROUP PTC EHF
    Inventors: Mayur Devjibhai Khunt, Sandipan Prabhurao Bondge, Nilesh Sudhir Patil, Haushabhau Shivaji Pagire, Nitin Sharadchandra Pradhan
  • Publication number: 20120269871
    Abstract: Provided herein are novel crystalline forms of rasagiline salts, processes for their preparation, pharmaceutical compositions, and method of treating thereof. The rasagiline salts include a maleate salt, a mandelate salt, or a salicylate salt.
    Type: Application
    Filed: December 29, 2010
    Publication date: October 25, 2012
    Applicant: ACTAVIS GROUP PTC EHF
    Inventors: Nilesh Sudhir Patil, Haushabhau Shivaji Pagire, Neela Praveen Kumar, Nitin Sharadchandra Pradhan
  • Publication number: 20110313176
    Abstract: Provided herein are convenient, industrially advantageous and environmentally friendly processes for the preparation of (?)-(S)-5-hydroxy-2-[N-n-propyl-N-2-(2-thienyl)ethylamino]tetralin (rotigotine) or a pharmaceutically acceptable salt thereof. Provided further herein is a highly pure rotigotine or a pharmaceutically acceptable salt thereof substantially free of impurities, processes for the preparation thereof, and pharmaceutical compositions comprising highly pure rotigotine or a pharmaceutically acceptable salt thereof substantially free of impurities.
    Type: Application
    Filed: December 22, 2009
    Publication date: December 22, 2011
    Applicant: ACTAVIS GROUP PTC EHF
    Inventors: Mayur Devjibhai Khunt, Shrikant Varma, Nilesh Sudhir Patil, Haushabhau Shivaji Pagire, Nitin Sharadchandra Pradhan
  • Patent number: 7947699
    Abstract: Described is a highly stable amorphous form of imatinib mesylate having a water content of less than 0.5 percent by weight, based on the total weight of the amorphous imatinib mesylate, (anhydrous amorphous imatinib mesylate), a process for preparation thereof, and pharmaceutical compositions.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: May 24, 2011
    Assignee: Actavis Group PTC EHF
    Inventors: Mayur Devjibhai Khunt, Nilesh Sudhir Patil, Haushabhau Shivaji Pagire, Nitin Sharadchandra Pradhan, Jon Valgeirsson
  • Publication number: 20110117200
    Abstract: Provided herein is rasagiline mesylate having a 90 volume-percent of the particles (D90) with a size of about 600 microns to about 1500 microns, and a process for the preparation thereof. Provided also herein are pharmaceutical compositions comprising rasagiline mesylate particles having a particle size which is suitable for homogeneous distribution of the drug substance in a tablet blend, in particular 90 volume-percent of the particles (D90) have a size of about 255 microns to about 1500 microns, and a process the preparation thereof.
    Type: Application
    Filed: March 31, 2009
    Publication date: May 19, 2011
    Applicant: ACTAVIS GROUP PTC EHF
    Inventors: Nilesh Sudhir Patil, Haushabhau Shivaji Pagire, Praveen Kumar Neela, Nitin Sharadchandra Pradhan, Jon Valgeirsson
  • Publication number: 20100330130
    Abstract: Provided herein are impurities of imatinib, N-(2-Methyl-5-methylamino-phenyl)-N-(4-pyridin-3-yl-pyrimidin-2-yl)-formamide (formamide impurity) and 4-[4-(Imidazole-1-carbonyl)-piperazin-1-ylmethyl]-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide (carbonylimidazole impurity), and processes for the preparation and isolation thereof. Provided further herein is a highly pure imatinib or a pharmaceutically acceptable salt thereof substantially free of formamide and carbonylimidazole impurities, processes for the preparation thereof, and pharmaceutical compositions comprising highly pure imatinib or a pharmaceutically acceptable salt thereof substantially free of impurities. Disclosed also herein is a process for preparing substantially pure ?-form of imatinib mesylate.
    Type: Application
    Filed: May 18, 2010
    Publication date: December 30, 2010
    Applicant: ACTAVIS GROUP PTC EHF
    Inventors: Mayur Devjibhai KHUNT, Nilesh Sudhir PATIL, Haushabhau Shivaji PAGIRE, Nitin Sharadchandra PRADHAN
  • Publication number: 20090181977
    Abstract: Described is a highly stable amorphous form of imatinib mesylate having a water content of less than 0.5 percent by weight, based on the total weight of the amorphous imatinib mesylate, (anhydrous amorphous imatinib mesylate), a process for preparation thereof, and pharmaceutical compositions.
    Type: Application
    Filed: January 9, 2009
    Publication date: July 16, 2009
    Applicant: Actavis Group PTC ehf
    Inventors: Mayur Devjibhai Khunt, Nilesh Sudhir Patil, Haushabhau Shivaji Pagire, Nitin Sharadchandra Pradhan, Jon Valgeirsson